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Abstract: p53 is one of the most intensively studied tumor suppressors. It transcriptionally regulates
a broad range of genes to modulate a series of cellular events, including DNA damage repair,
cell cycle arrest, senescence, apoptosis, ferroptosis, autophagy, and metabolic remodeling, which are
fundamental for both development and cancer. This review discusses the role of p53 in brain
development, neural stem cell regulation and the mechanisms of inactivating p53 in gliomas.
p53 null or p53 mutant mice show female biased exencephaly, potentially due to X chromosome
inactivation failure and/or hormone-related gene expression. Oxidative cellular status, increased
PI3K/Akt signaling, elevated ID1, and metabolism are all implicated in p53-loss induced neurogenesis.
However, p53 has also been shown to promote neuronal differentiation. In addition, p53 mutations
are frequently identified in brain tumors, especially glioblastomas. Mechanisms underlying p53
inactivation in brain tumor cells include disruption of p53 protein stability, gene expression and
transactivation potential as well as p53 gene loss or mutation. Loss of p53 function and gain-of-function
of mutant p53 are both implicated in brain development and tumor genesis. Further understanding
of the role of p53 in the brain may provide therapeutic insights for brain developmental syndromes
and cancer.
Keywords: p53; brain; development; neural stem cell; glioma; mutation; gain-of-function

1. Introduction
Over 40 years ago, a ~53-kDa protein was detected with high expression levels in cancer cells [1–3],
igniting the explosive field of p53 research. Since then, a large number of researches have revealed and
are still revealing the potential value and mechanisms of p53 in cancer both in vitro and in vivo [4–6].
p53 gene, which encodes the transcription factor p53, has been identified as the most frequently mutated
tumor suppressor gene in human cancers. Mutations in p53 or activation of pathways that suppress
p53 largely contribute to malignant transformation in a variety of cancers. The tumor suppression
function of p53 is fundamentally linked to a variety of central cellular events such as DNA damage
repair, cell cycle arrest, apoptosis, senescence, autophagy, ferroptosis, and metabolism, mainly through
transcriptional regulation of p53 target genes [7,8].
Meanwhile, evidence of p530 s critical roles in development is also mounting [9]. In normal cells,
p53 level is maintained low due to ubiquitination and protein degradation mediated by E3-ubiquitin
ligase such as MDM2 [10] (For the full name of genes mentioned in this article, please refer to the
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spina bifida (open neural tube in spinal cord), ocular abnormalities and defects in upper incisor
tooth formation [13,20,21]. p53-dependent apoptosis seems to only play at most a partial role during
normal neural tube closure, as indicated by subtle reduction of apoptosis in the p53−/− embryos [14].
A significant number of p53−/− mice bypass embryonic lethality [13,14], indicating that p53 is probably
only transiently required in specific cells and p53 loss can be compensated by other mechanism(s).
In addition, the p53N236S/N236S mice displayed female-specific exencephaly and spina bifida [22]
(Table 1). The occurrence rate of exencephaly was much higher than that in the p53−/− females
(68.5% vs. 37.1%). Plus, the p53N236S mutation led to decreased neuroepithelial differentiation and
apoptosis, and increased neuroepithelial proliferation in comparison to p53 loss. These findings suggest
gain-of-function (GOF) of p53N236S in NTDs [22]. Hitherto, to our best knowledge, no comparison of
NTDs phenotype has been made between mice containing other p53 hot spot mutations and p53 deficient
mice. It will be interesting to determine whether the increased NTDs incidence is a p53N236S-specific
effect, or it can also be caused by other p53 hot spot mutations. A variety of mechanisms, such as
inhibiting p53 family proteins p63 and p73, have been suggested to underlie the GOF of mutant p53
during tumor genesis and progression [23], and p73-deficient mice show profound defects in brain
development, including hydrocephalus and hippocampal dysgenesis [24]. Further investigation is
needed to reveal the mechanisms through which p53 loss or GOF regulates neural tube closure.
It is interesting to notice that the NTDs was primarily found in the female p53−/− or p53N236S/N236S
mouse embryos. The cause of this female bias in NTDs has long been postulated to be defective
X chromosome inactivation [25], which remained unproven. A recent study, taking advantage of
the 100% penetrant, female-exclusive NTDs observed in double loss of pro-apoptotic Bim and p53,
shed light on the female-specific functions of p53 during neural tube closure [26]. It showed that in
female p53−/− ;Bim+/− E9.5 embryonic neural tube samples X chromosome markers Xist and H3K27me3
was decreased and X-linked gene expression was increased at both RNA and protein levels. Moreover,
p53 directly bound response elements in the X chromosome inactivation (XCI) center. Interestingly,
the incidence of NTDs in the absence of intrinsic apoptosis by completely deleting Bax, Bak, and/or Bok
was very low and was not biased to female embryos. These data suggest that loss of p53 that causes
stochastic failure in X chromosome inactivation (XCI), instead of lack of developmental apoptosis alone,
contributes to the female bias in NTDs. Nevertheless, the molecular mechanism for how XCI failure
causes female specific NTDs needs to be further elucidated. The XCI failure has also been suggested
to underlie the p53N236S-induced NTDs [22]. Alternatively, p53 has been implicated in regulating
estrogen receptors (ER), either by regulating the expression level of ERα [27,28] or competing for the
estrogen-responsive target gene promoters [29]. Meanwhile, p53 is a target gene of ERα [30]. It is
noteworthy that sexual dimorphism in the expression of sex hormone receptors in mammalian brains
have been observed [31,32]. One can speculate that the development of the female brain, which exhibits
gender-specific pattern of sex hormone receptor expression, is probably more heavily dependent on
p53 and thus more vulnerable to p53 disruption in comparison to that of the male brain.
Interestingly, while p53 deficiency leads to neural tube abnormality, over-expression of p53 also
causes NTDs. Ablation of Pax-3 resulted in elevated p53 protein level and NTDs in mouse embryos,
which could be rescued by loss of p53 [33] (Table 1). Recently, it was shown that zinc deficiency
led to increased p53 stabilization and neural tube closure failure, which could be overcome by p53
transcriptional activity inhibitor [34].
Additionally, p53 stabilization can also lead to other brain developmental phenotypes. When the
negative regulator of p53, MDM2, was ablated specifically in the CNS, mice developed hydranencephaly
at embryonic day 12.5 due to apoptosis, whereas the deletion of MDM4, another p53 negative
regulator, generated a porencephaly phenotype at embryonic day 17.5 because of cell cycle arrest and
apoptosis [35] (Table 1). Both phenotypes could be completely rescued by concurrent p53 deletion.
Strikingly, deletion of both Mdm2 and Mdm4 genes led to an even earlier and more severe CNS
phenotype [35]. These findings indicate the dosage effect of p53 and suggest that p53 level needs to be
precisely regulated during brain development.
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Table 1. Mouse models exhibiting p53-dependent brain developmental phenotypes.
Mouse Models
p53−/− [13,14]
p53N236S/N236S

[22]
p53−/− ; Bim+/− [26]
Pax3Sp/Sp [33]
FM/+
Mdm2
; Nestin-Cre [35]
Mdm4FX/+ ; Nestin-Cre [35]
Nbnflox/flox ; Nestin-Cre [36]
Nde1−/− [37]
Cep63T/T [38]
Tubb5E401K/E401K ; Nestin-Cre [39]
Tubb5flox/+ ; Nestin-Cre [39]
Eif4a3flox/+ ; Emx1-Cre [40]
Rbm8aflox/+ ; Emx1-Cre [40]
Magohflox/+ ; Emx1-Cre [40]
CitK−/− [41]
Kif20bm/m [42]
AspmSA/SA [43]
Aspmflox/flox ; Math1-Cre [43]
p53515C/515C ; Mdm2−/− [44]

p53-Dependent Brain Developmental
Phenotypes

p53 Status

Female-specific exencephaly, spina bifida,
retinal dysplasia
Female specific exencephaly and spina bifida
100% penetrate, female-exclusive exencephaly
Exencephaly
Hydranencephaly
Porencephaly
Microcephaly
Microcephaly
Microcephaly

p53 missense mutation
p53 deletion
p53 stabilization
p53 stabilization
p53 stabilization
p53 stabilization
p53 stabilization
p53 stabilization

Microcephaly

p53 stabilization

Microcephaly
Microcephaly
Microcephaly
Microcephaly
Microcephaly

p53 stabilization
p53 stabilization
p53 stabilization
p53 stabilization
p53 stabilization

Microcephaly (hypoplastic cerebellum)

p53 stabilization

Cerebellar defects

Mutant p53
stabilization

p53 deletion

Note: p53-dependent brain developmental phenotypes in these models are caused by p53 deletion, mutation or p53
protein stabilization. Some mouse models may also exhibit non-CNS phenotypes that are not described here.

In addition, a number of in vivo studies have demonstrated that p53-dependent apoptosis or
proliferation defects is profoundly involved in microcephaly caused by removal or mutation of a variety
of molecules in mouse CNS (Table 1), including DNA damage repair protein NBN1 [36], the scaffold
protein NDE1 [37], centrosomal protein CEP63 [38], tubulin TUBB5 [39], RNA metabolism protein
EIF4A3 [40], RNA binding protein RBM8A [40], spliceosome component protein MAGOH [40],
citron kinase protein CITK [41], or kinesin-like protein KIF20B [42]. In these mouse models,
p53 protein was stabilized and p53 deletion could largely rescue the microcephaly phenotype [36–42].
p53 activity also contributes to hypoplastic cerebellum resulted from deletion of Aspm, a gene
that is mutated in familial microcephaly and in cerebellar granule neuron progenitors [43]. Lastly,
the p53515C/515C ;Mdm2−/− mice, which contain stabilized p53R172P, a p53 mutant protein that lacks
apoptotic function but is able to elicit a partial cell cycle arrest, displayed proliferative defects in the
cerebellum starting from postnatal day 4–6 [44] (Table 1), suggesting that restrained p53-dependent
cell cycle arrest is also essential for the normal postnatal cerebellar development.
It is intriguing that stabilization of WT p53 via deletion or mutation of the above listed
different genes can lead to different CNS defects including NTDs, hydranencephaly, porencephaly,
and microcephaly (Table 1). Cell-specific and time-dependent p53 stabilization may account for
the phenotype variations. In addition, stabilized p53 is probably not the sole determinant of these
phenotypes. Alteration of these different genes may not only stabilize p53 but also activate specific
partners of p53 that have not been identified by the above studies but are in fact co-essential for
causing the specific defects. Since both p53 and the yet-to-be-determined co-factors are required for
the abnormal brain developmental phenotypes, suppression of p53 from an aberrantly high level is
sufficient for restoring the normal development. This may also explain why the “Super p53” mice
that carry an extra, fully functional copy of the p53 gene did not seem to exhibit any developmental
abnormalities [45] and disruption of the Mdm2 E3 ligase function did not generate any brain defects [46],
although the dosage effect of p53 may also contribute to the discrepancy.
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In summary, loss/mutation of p53 or stabilization of p53 may both lead to NTDs. The female specific
NTDs may be due to X-chromosome inactivation failure or hormone-related gene regulation. In addition
to NTDs, p53 is also involved in other CNS developmental phenotypes such as hydranencephaly,
porencephaly, microcephaly, and cerebellar defects. Further investigations are needed to determine
why p53 stabilization can cause different brain developmental defects.
3. p53 and Neural Stem Cell Regulation
Neural stem cells (NSCs) are multipotent cells, which can self-renew and proliferate without limit,
to produce neural progenitor cells (NPCs) that terminally differentiate into neurons, astrocytes and
oligodendrocytes [47]. Emerging evidence has indicated that p53 plays important roles in the regulation
of NSC/NPC differentiation. In one study, the p53−/− mouse brains showed much higher levels of neuron
markers Tuj1, MAP2 or NeuN at E11.5, E13.5, or E17.5, but lower levels of astrocyte marker GFAP at E17.5
than WT embryos, suggesting that p53 deficiency promotes neuron differentiation but inhibits astrocyte
differentiation at this stage of development [48]. In another study, differentiating E13 p53−/− neural
progenitor cells exhibited enhanced expression of neurogenic genes and displayed greater extension of
neurites, while astrogliogenesis was not affected [49]. In addition, both GABAergic and glutamatergic
differentiation was enhanced in p53−/− cells. Importantly, in line with the results in cell culture,
expression of the neuroblast marker DCX, as well of the GABAergic neuron marker GAD65/GAD67,
was elevated between E13 and E16 in the p53−/− telencephalons, whereas astrogliogenesis was not
affected [49]. The suppressive role of p53 in neurogenesis has also been observed in human iPS derived
neural embryonic stem (NES) cells, as indicated by an upregulation of neuronal differentiation genes
in p53 knockdown (p53KD) NES cells [50]. Furthermore, direct inactivation of p53 by SV40 large T
antigen, a short hairpin RNA against p53, or genetic ablation of p53 in Dgcr8−/− pluripotent stem cells
(PSCs) enabled neural differentiation, while activation of p53 by the MDM2 inhibitor nutlin-3a in WT
embryonic stem cells inhibited neural differentiation [51].
Efforts have been made to understand the underlying molecular mechanisms through which
p53 suppresses neurogenesis. The aforementioned study has suggested that the premature onset of
neurogenesis in p53−/− NPCs is at least in part due to a more oxidative cellular status and increased
PI3K/AKT signaling in neural progenitors [49]. In addition, elevated Smad1 expression/activation in the
p53−/− mouse brain and NSC was demonstrated to contribute to the accelerated neuronal differentiation.
The expression of ID1 is repressed by p53 in BMP-SMAD1-dependent and independent manners.
P53 deficiency caused upregulation of ID1 expression, which in turn accelerated neuronal differentiation
of NSCs [48]. Furthermore, downregulation of genes involved in oxidative phosphorylation (OXPHOS)
and an upregulation of glycolytic capacity might be also responsible for the increased neuronal
differentiation of p53KD NES cells [50], suggesting that p53 acts as a regulator of metabolism in human
neural stem cells in addition to its role in cancer metabolism. Considering p53 is a transcription factor
that regulates perhaps several thousands of genes with diverse biological functions, it can be speculated
that more underlying pathways await to be elucidated.
Intriguingly, p53 can also promote neuronal differentiation as shown in other studies. For example,
overexpression of WT p53 enhanced nerve growth factor-mediated neuronal differentiation in PC12
cells, while mutant p53 or knockdown of endogenous WT p53 inhibited it, the latter of which
could be rescued by over expression of WT p53 [52]. SCY1-like 1-binding protein, which decreased
p53 protein level, inhibited NGF-mediated neurite outgrowth in PC12 cells [53]. Mechanistically,
p53 was suggested to direct interact with and activate the neurotrophin receptor TrkA, stimulating
ERK-dependent neuronal differentiation [52,54,55].
This puzzling discrepancy in the roles of p53 in neuronal differentiation may be partially due
to different model systems (mouse vs. cell culture) being used. In addition, whether p53 promotes
NSC/NPC proliferation is also controversial. In several studies, loss of p53 provided a proliferative
advantage to neural stem cells/progenitor cells in mouse brain [48,56], which has been suggested to
deploy different regulatory networks governing neurogenesis in comparison to human brain [57].

Biology 2020, 9, 285

6 of 13

Therefore, caution must be exercised when interpreting the findings. In fact, using human induced
pluripotent stem cell-derived neural stem cells, it was demonstrated that instead of promoting cell
division, p53 deficiency resulted in slower neuronal stem cell proliferation, potentially due to a
prolonged G2 phase [50]. The reduced proliferation rate has also been observed in the p53 knock-down
3D brain organoid system; however, this exploits a different mechanism by accumulating cells in G1
phase at the expense of S phase [50]. The discrepancy between a 2D and 3D system reinforces the
notion that brain development is a process under extremely delicate regulation and again warrants the
necessity of caution during data interpretation.
In summary, emerging evidence has shown that p53 inhibits neuronal differentiation of NSCs.
Oxidative cellular status, increased PI3K/Akt signaling, elevated ID1 and metabolism are all
implicated in p53-loss induced neurogenesis. However, p53 has also been shown to promote neuronal
differentiation. The role of p53 in NSC/NPC proliferation is also controvertible. Different model systems
used in different studies may partially account for these discrepancies.
4. p53 and Brain Cancer
The most common malignant brain tumors in adults are diffuse gliomas, which are further
classified into astrocytomas (WHO Grade II and III), oligodendrogliomas (WHO Grade II and III),
oligoastrocytoma (WHO Grade II and III), and glioblastomas (WHO Grade IV) [58]. The common
genetic alterations found in astrocytomas occurs in p53 [59]. In addition, around 12% of Li-Fraumeni
syndrome patients with germline p53 mutations develop brain tumors, including mostly astrocytomas in
adults and medulloblastoma in children [16]. Among all brain cancers, glioblastoma multiforme (GBM)
is the most aggressive and confers the poorest prognosis. It can be divided into two diseases—primary
and secondary GBM. p53 exhibits different mutation frequency in these two categories. It is mutated
in ~30% of primary GBM and identified around in 65% secondary GBM [60]. The number is even
higher if alteration of p53 pathways is taken into consideration. For example, 84% of GBM patients and
94.1% of GBM cell lines contain deregulated ARF-MDM2-p53 pathway [60]. Additionally, GBM can be
subdivided into different molecular subtypes based on their differing mutational patterns: Proneural,
mesenchymal, neural, and classical, which exhibit different prevalence of p53 mutations (54%, 32%,
21%, and 0%, respectively) [61]. The majority of p53 mutations is missense mutation. Three hotspot
codons, R248, R273 and R175, in the DNA binding domain of p53 represent the highest mutation
frequency according to the GBM PanCancer Atlas of The Cancer Genome Atlas (TCGA). In addition
to mutations in the coding sequence, splice site mutation of p53 gene has also been identified in
diffuse astrocytomas [62]. Additionally, p53 promoter methylation was found in 21.4% of 42 primary
GB tumors, which, however, was not associated with p53 mRNA or protein level [63]. Instead,
p53 mutation is significantly corelated to p53 protein but not mRNA levels [63]. Thus, the significance
of this methylation needs to be further investigated. Nevertheless, the direct evidence for p530 s roles
in brain tumorigenesis and progression was obtained from a number of mouse models that carry
disrupted p53 gene alone, or in combination with oncogenes or other inactivated tumor suppressors.
These mouse models have been extensively discussed previously [64].
A variety of mechanisms of inactivating p53 to promote brain tumor have been revealed (Table 2).
Firstly, p53 activity can be dampened by impairing its protein stability [15], including disruption of
the ARF/MDM2/MDM4/p53 pathway [65–71], genomic loss of DNA-damage response factors ATM
and CHEK2 [72], and tumor suppressor CHD5 [73]. Secondly, p53 can also be neutralized at the
transcriptional level. For example, p53 has been recently identified as a transcriptional target of Parkin.
Somatic mutations on Parkin have been linked to glioma genesis [74]. Interestingly, p53 was also found
to regulate Parkin transcription via its DNA binding properties. Parkin expression in mice brain was
increased after p53-bearing viral infection [74], suggesting a functional interplay between p53 and Parkin
in brain tumorigenesis. IDH1 Arg-132 mutants, R132H/R132Q, which produces extremely high levels
of intracellular 2-hydroxyglutarate, suppressed p53 expression through stabilizing hypoxia-inducible
factor-2α that activates the expression of miR-380-5p, a characterized microRNA that is against p53

Biology 2020, 9, 285

7 of 13

expression [75]. Rescue expression of p53 can inhibit the proliferation rate and impair the resistance of
apoptosis induced by doxorubicin in IDH1 R132Q mouse embryonic fibroblast cells [75]. Furthermore,
p53 protein levels correlate negatively with IDH1 R132H levels in human glioma samples [75].
This study also suggests that, while p53 mutation can affect cell metabolism, cell metabolism could vice
versa impact p53 genetically, resulting in tumor phenotypes [75]. In addition, the transcription factor
NF1A, was recently found to have GBM-promoting effects, which were mediated via transcriptional
repression of p53, p21, and PAI1 through specific NFIA-recognition sequences in their promoters [76].
MicroRNA 141-3p, the expression of which positively correlates with the malignance degrees of gliomas,
has also been suggested to promote glioblastoma progression and temozolomide resistance by altering
p53 expression [77]. Thirdly, overexpression of Bck2L12 protein in primary GBMs has been found to
bind to p53 and impair its transactivation potential, inhibiting p53-mediated cellular senescence and
cell death [78,79]. Similarly, macrophage migration inhibitory factor (MIF), which was found to be
highly expressed in brain tumor-initiating cells (BTIC) in human brain tumor specimen and promote
BTIC-induced tumor formation in mouse xenografts, physically interacts with and inhibits p53 [80].
Lastly, it has become evident that impairment of oxidative metabolism via inhibition of complex 1 or
decreased mitochondrial DNA copy number could lead to p53 genetic inactivation and transformation
of neural stem cells, which act as the cells of origin for high-grade glioma [81].
Table 2. Mechanisms of inactivating p53 in brain tumors.
Suppressing p53 Gene
Expression

Impairing p53 Protein
Stability
•

•

•
•
•

Gene
amplification of
MDM2 and
MDM4 [66,67]
Genetic deletion
and methylation
of ARF [65]
Genomic loss of
ATM [72]
Genomic loss of
CHEK2 [72]
Genomic loss of
CHD5 [73]

•
•

•
•

Disrupting p53
Transactivation Potential

Mutation of Parkin [74]
IDH1 R132Q mutant
(causes activation of the
•
2-HG/HIF-2a/miR-380-5p
pathway) [75]
•
Overexpression of
NFIA [76]
Overexpression of
miR-141-3p [77]

Overexpression of
Bcl2L12 [78,79]
Overexpression of
MIF [80]

Loss or Mutation of
p53 Gene

•

Inhibition of
mitochondrial
metabolism [81]

Mutant p53 has been reported to exhibit GOF in a variety of tumor types such as osteosarcoma,
lymphoma, leukemia, and lung and mammary adenocarcinomas [82]. Studies are also revealing that
p53 mutant may also possess GOF in brain tumors. In a recent study, p53M237I, which accumulates
within amyloid-like p53 oligomers in glioblastoma-derived cells, was indicated to exhibit GOF as cells
expressing the M237I-p53 mutant were more resistant to temozolomide (TMZ) treatment than cells
expressing WT p53 [83]. In another study, ectopic expression of p53R248L mutation promoted the
progression of GBM and enriched inflammation-related signatures [84]. However, one needs to be
cautious when elucidating the function of mutant p53 based on comparison between WT p53 tumors
and tumors overexpressing mutant p53, as the p53 mutants in these studies may simply exhibit loss
of WT tumor suppression function and/or exert a dominant negative effect by suppressing the WT
allele. In fact, when p53Y236delta (deletion of p53 codon 236) was transduced into the p53+/− or p53−/−
primary neuroectodermal cells, which were subsequently transplanted into the brain of the adult
WT mice, the presence of Y236delta in transplanted p53−/− cells had no effect on the tumor frequency
and did not affect the tumor latency regardless of the genotype of the transplant. On the other hand,
tumor arose from the p53+/− cells only when transduced with Y236delta. This clearly suggest that
Y236delta exerts dominant-negative activity but does not exhibit GOF in the study [85]. In another
study, expression of p53Y236delta in the astrocytes of p53+/− mice significantly reduced the latency
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of ENU-induced brain tumor but did not alter tumor penetrance [86]. Therefore, GOF mutant p53 is
dependent on cell type, cancerous features, and may be also codon-specific.
The current standard treatment for GBM patients is surgery followed by radiotherapy plus
concomitant adjuvant chemotherapy with TMZ. However, GBM is still considered incurable [60].
The pivotal role of p53 in GBM makes it a desirable target for therapy. The strategies include prevention
of WT p53 degradation, restoration of WT p53 function in mutant p53 tumors and inhibition of GOF
mutant p53. A large number of molecules including those that inhibit Mdm2/p53 complex (such as
Mdm2 inhibitors AMG232 and RG7112), restore WT p53 structure (such as PRIMA-1 and its analog)
and degrade mutant p53 (such as HDAC inhibitors) showed promising outcomes on GBM cells or
mouse models and have been discussed previously [60]. However, hitherto none of these molecules
have gone to clinic trials for GBM. The upcoming new decade may witness whether manipulation
of p53 with some of these molecules will benefit GBM patients. It is also desirable to broaden our
understanding of the roles p53 plays in GBM, which may shed light on therapies for this highly
malignant brain tumor.
In summary, p53 is frequently mutated in astrocytomas and GBM. Mechanisms of inactivating p53
in brain tumors include impairing p53 protein stability, suppressing p53 gene expression, disrupting
p53 transactivation potential and loss or mutation of p53 gene. GOF of mutant p53 may be involved in
brain tumors. However, more efforts are needed to differentiate the GOF and dominate negative effect
of mutant p53 in brain tumors.
5. Conclusions
p53 has been one of the most intensively and attractively studied proteins since it was discovered.
From a single amino acid alteration, p53 may lose its transcriptional activity and even exert a dominant
negative effect by binding to WT p53 protein. Mutant p53 can also experience a GOF and bind to DNA
via associating with other transcription factors to alter gene expression. The level of p53 needs to be
precisely regulated during development as both loss and overexpression of p53 can lead to abnormal
brain phenotypes. Whether p53 promotes or inhibits the neuronal differentiation of NSCs/NPCs
remains controversial. p53 is frequently mutated in brain tumors, with a higher mutation frequency in
glioblastomas. The disruption of p530 s functions via impairing its protein stability, gene expression,
transactivation potential and gene loss or mutation can lead to brain tumorigenesis. There are still
a number of remaining unresolved issues regarding the role of p53 in brain development, NSC and
brain cancer. These issues include, but are not limited to, the mechanism(s) of compensating p53 loss
during embryonic development, other molecular pathway(s) underlying loss or mutant p53-mediated
female-specific NTDs, mechanisms via which p53 promotes or inhibits neuronal differentiation of NSCs,
and causes brain cancer. In addition, mechanism(s) that play central roles in the above CNS pathologies,
elucidated from studies using in vitro cell cultures and animal models, need to be scrutinized when
translated to clinic. More research addressing these issues will provide insight for therapies regarding
brain developmental syndromes and cancer mediated by deregulated- or inactivated-p53.
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